AC Immune is focused on developing innovative Alzheimer’s disease therapies using vaccination or passive immunization with antibodies. Both the active and passive immunotherapy is directed against the beta amyloid protein which misfolds and forms plaques in Alzheimer’s disease.
The patent-protected antigen technology of AC Immune provides highly efficient immunization and solubilization of the plaques by inducing transition from the insoluble to the soluble form of the beta amyloid protein.
The company’s pipeline is comprised of three compounds entering into clinical development in 2006/2007. This latest financing provides the funds to complete phase I of at least one molecule in development.
“After obtaining encouraging results in animal studies showing the unique features of AC Immune’s immunotherapeutic approach, we are very excited to move into the next phase of testing our lead molecules for clinical submission,” said Andrea Pfeifer, CEO of AC Immune.